AbbVie Inc
Veridion Score
Composite trend over time
Why is ABBV moving today?
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
ABBV insider activity
AbbVie Inc
3 insiders bought in the last 90 days
Net selling: -$41.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | 2026-03-31 | Quaggin Susan E | Insider | buy | $217.49 | 71 | 784 | $15K | SEC Form 4 |
| 2026-04-02 | 2026-03-31 | Alpern Robert J | Insider | buy | $217.49 | 35 | 10,369 | $8K | SEC Form 4 |
| 2026-04-02 | 2026-03-31 | RAPP EDWARD J | Insider | buy | $217.49 | 155 | 28,865 | $34K | SEC Form 4 |
| 2026-03-11 | 2026-02-27 | Purdue David Ryan | Insider | sell | $232.08 | 2,108 | 8,468 | $489K | SEC Form 4 |
| 2026-03-06 | 2026-03-04 | Purdue David Ryan | Insider | sell | $233.56 | 5,230 | 2,654 | $1.2M | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 33 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moABBV contract awards, year to date.
Public federal awards linked to this ticker.
ABBV lobbying filings, year to date.
Registered lobbying filings matched to AbbVie Inc.